ct-388 peptide peptide - CT-388Roche 388 Unveiling CT-388: A Promising Dual Agonist for Obesity and Type 2 Diabetes

CT-388Phase 3 The landscape of metabolic disease treatment is rapidly evolving, with a significant focus on novel therapeutic agents that address both weight management and glycemic controlCT 388 is a subcutaneously administered peptidethat acts as a dual agonist of the gastric inhibitory polypeptide receptor (GIP) and .... Among these emerging treatments, CT-388 peptide stands out as a particularly promising investigational compound. Developed by Roche, CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist designed to combat obesity and type 2 diabetes (T2D). This article delves into the scientific underpinnings, clinical progress, and potential impact of CT-388, aiming to provide a comprehensive overview for both healthcare professionals and interested individuals.

Understanding the Mechanism of Action: A Dual Receptor Approach

At its core, CT-388 is a peptide engineered to selectively activate two critical receptors in the body: the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR).作者：M CHAKRAVARTHY·2023·被引用次数：10—75-LB:CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four ... This dual agonism is a key differentiator, allowing CT-388 to harness the benefits of both incretin hormones.

GLP-1, a hormone released after meals, plays a vital role in regulating blood glucose by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. GIP, another incretin hormone, also enhances insulin secretion in a glucose-dependent manner and has been shown to contribute to fat metabolism and adipogenesis. By simultaneously targeting both GLP-1 and GIP receptors, CT-388 aims to offer a more comprehensive and potent effect on appetite suppression, energy expenditure, and glucose homeostasis compared to single-agonist therapies. Early research, including studies in mice and monkeys, has demonstrated that CT-388 improved glycemic control and led to significant reductions in body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis.

Clinical Development and Efficacy Data

The journey of CT-388 from laboratory to potential widespread use is marked by ongoing clinical trials. The compound is being investigated in several studies, including a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate its efficacy and safetyEffects of CT-388, a once-weekly signaling-biased dual ....

Recent topline results from a Phase II clinical trial have generated considerable excitement. In the CT388-103 study, a 24mg dose of CT-388 demonstrated impressive results, with 54 percent of participants achieving resolution of obesity. Further data from this trial revealed that adult participants with obesity lost up to 22.1天前—CT-388is a dual glucagon-likepeptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist that is under development for the ...5% of their body weight at 48 weeks作者：MV Chakravarthy·2025—CT-388 is being developed as a once-weekly injectable therapy for obesity and type 2 diabetes. Abstract. Biased agonism of the glucagon-like peptide-1/glucose- .... When analyzed using the treatment-regimen estimand, the placebo-adjusted weight loss achieved with CT-388 was 18.3%2024年5月17日—在具有前期糖尿病的患者子族群中，CT-388治療使所有患者的血糖恢復正常，顯示出藥物對血糖平衡的效果。此外，CT-388的安全性和耐受性與其藥物類別一致，治療 .... These findings highlight the significant potential of CT-388 in achieving substantial and sustained weight reduction, a critical unmet need in the management of obesity.

Moreover, CT-388 administered once-weekly resulted in clinically meaningful weight loss and improvements in insulin sensitivity over a four-week treatment period in participantsRoche Obesity Drug's Phase 2 Results Are Competitive .... In individuals with pre-existing type 2 diabetes, CT-388 treatment led to the normalization of blood glucose levels, showcasing its dual therapeutic capacity. The safety and tolerability profile of CT-388 has been reported to be consistent with its drug class, which is a crucial factor for long-term treatment adherence and patient well-being.

The Future of CT-388: From Phase 2 to Phase 3 and Beyond

The positive outcomes from Phase II trials have paved the way for CT-388 Phase 3 testing, with Roche planning to advance the drug into this critical phase by the end of March. This progression signifies a strong belief in the compound's therapeutic potential. The CT-388 clinical trial data suggests that this novel once-weekly dual GLP-1 and GIP receptor modulator is not only safe and well-tolerated but also capable of producing significant weight lossRoche GLP-1 produces “robust” weight loss in phase II ....

While CT-388 is positioned to enter the competitive obesity market, its development trajectory is noted to be several years behind established treatments like Zepbound. However, the unique dual GLP-1/GIP receptor agonist mechanism of CT-388 offers a distinct advantage, potentially providing additional benefits for specific patient segmentsRoche, trailing in obesity, showcases new data for GLP-1 .... The pipeline for future medications for obesity is expanding, and CT-388 is a significant contender.

The structure of CT-388 as a peptide allows for subcutaneous administration, typically once weekly, making it a convenient option for patients.Roche, trailing in obesity, showcases new data for GLP-1 ... Research into CT-388-104 and other specific study protocols is ongoing, aiming to further elucidate its long-term efficacy and safety.

Comparison with Other Treatments

The emergence of CT-388 places it in dialogue with other incretin-based medications, such as those targeting GLP-1 receptors alone. While the exact comparison of efficacy against specific drugs like Ozempic (which is semaglutide, a GLP-1 agonist) requires further head-to-head studies, the dual agonism of CT-388 offers a different therapeutic strategyIs GLP-1 the Same as Ozempic?. The question of which GLP-1 drug is best for weight loss is complex and depends on individual patient factors and treatment goalsCarmot Therapeutics Highlights Clinical Data from its .... However, the robust weight loss observed with CT-388, reaching up to 22.5%, positions it as a highly competitive option. Discussions around alternatives like berberine, sometimes dubbed "nature's Ozempic," highlight the growing interest in metabolic health, but CT-388 represents a precisely engineered pharmaceutical intervention.

Conclusion

CT-388 represents a significant advancement in the quest for effective treatments for obesity and type 2 diabetesA Study of CT-388 in Participants Who Are Overweight or O.... As a peptide acting as a dual GLP-1/GIP receptor agonist, it offers a compelling mechanism of action with demonstrated efficacy in clinical trials. The Roche's CT-388 Phase 2 results, showing substantial weight loss and improved glycemic control, underscore its potential to transform the lives of millions. With its progression into CT-388 Phase 3 trials, the medical community eagerly anticipates further data that could solidify CT-388's role as a vital therapeutic option in the ongoing fight against metabolic diseasesCT 388 is a subcutaneously administered peptidethat acts as a dual agonist of the gastric inhibitory polypeptide receptor (GIP) and .... The development of compounds like CT-388 signifies a commitment to innovation and a hopeful future for individuals seeking effective management of their health.